- Erasca Reports First Quarter 2024 Business Updates and Financial Results
- Erasca Announces $45 Million Oversubscribed Private Placement Financing
- Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
- Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
- Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
- Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
- Erasca Reports Third Quarter 2023 Financial Results and Business Updates
- Erasca to Present at Upcoming Investor Conferences in November
More ▼
Key statistics
As of last trade Erasca Inc (ERAS:NSQ) traded at 2.84, -15.82% below its 52-week high of 3.38, set on Jun 06, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.59 |
---|---|
High | 2.92 |
Low | 2.51 |
Bid | 2.84 |
Offer | 2.85 |
Previous close | 2.44 |
Average volume | 3.63m |
---|---|
Shares outstanding | 237.98m |
Free float | 203.04m |
P/E (TTM) | -- |
Market cap | 580.68m USD |
EPS (TTM) | -0.8423 USD |
Data delayed at least 15 minutes, as of May 23 2024 16:13 BST.
More ▼